VYNE Therapeutics is a pharmaceutical company. Co.'s products include AMZEEQ® (minocycline) topical foam, 4% for the treatment of inflammatory lesions of moderate-to-severe acne vulgaris in adults and patients nine years of age and older, and ZILXI® (minocycline) topical foam, 1.5% for the treatment of inflammatory lesions of rosacea in adults. Co.'s product pipeline includes FCD105 (minocycline 3% and adapalene 0.3%), its proprietary topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris. In addition, Co.'s development program, FMX114, is a combination topical gel for the treatment of mild-to-moderate atopic dermatitis. We show 8 historical shares outstanding datapoints in our coverage of VYNE's shares outstanding history.
Understanding the changing numbers of VYNE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VYNE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VYNE by allowing them to research VYNE shares outstanding history
as well as any other stock in our coverage universe. |
Free VYNE Email Alerts:
Video: Shares Outstanding Importance
